Alzheimers-300x127Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has announced an agreement with the Dutch biotech company Crossbeta Biosciences BV to utilize Crossbeta’s proprietary technology in support of Probiodrug’s  biomarker development activities.

AD, the most common form of dementia affecting 26 million people worldwide, is characterized by misfolded beta-amyloid and tau proteins. The oligomeric forms of these proteins play a pivotal role in the pathophysiology of the disease.

Oligomer-specific research and development of therapeutics, biomarkers and diagnostics is very challenging because of the inherent instability of these protein aggregates. Crossbeta’s proprietary stabilization technology generates pure and functional preparations of oligomeric protein species and thereby overcomes this problem, enabling highly reproducible and well-controlled assays for preclinical and clinical R&D.

Inge Lues, Chief Development Officer of Probiodrug, commented: “We are very pleased to announce the collaboration with Crossbeta. The potential of Crossbeta’s unique technology has significant impact to overcome the challenge of establishing and validating sensitive and specific assays for Abeta- and pGlu-Abeta-oligomers to be used in the clinical studies of Probiodrug’s lead candidate, Glutaminyl Cyclase (QC) inhibitor PQ912.”

Guus Scheefhals, Chief Executive Officer of Crossbeta, added: “This strategic partnership with Probiodrug is very exciting and an important recognition of our expertise and capabilities. As a clinical-stage company, Probiodrug is a particularly important partner in our growing collaborative network. We look forward to contributing towards the development of this promising therapeutic approach targeting AD.”